Notably, MEK and EGFR inhibitors cooperate to block EGFR inhibitor-resistant CRC tumor growth,33 and we propose therefore that CCT3833 is effective in CRC because it targets the two key pathways downstream from mutant RAS and the hyperactivated receptor tyrosine kinases such as EGFR. Here, EGFR is linked to colorectal carcinoma.